Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.

Rapat PittayanonPanida PiyachaturawatRungsun RerknimitrPiyapan PrueksapanichSupakarn ChaitongratVorarit LertsuwunseriSuphot SrimahachotaVarocha Mahachai

Published in: Journal of gastroenterology and hepatology (2019)

Rebamipide is safe and may prevent peptic ulcers ≥ 5 mm in diameter or those with pigmented spots in patients receiving dual antiplatelets for 1 year (NCT02166008).

Keyphrases

double blind
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
prognostic factors
study protocol
placebo controlled
randomized controlled trial
wound healing